PharMerica Co. (NYSE:PMC) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund cut its holdings in shares of PharMerica Co. (NYSE:PMC) by 36.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,000 shares of the company’s stock after selling 17,854 shares during the period. New York State Common Retirement Fund owned about 0.10% of PharMerica worth $908,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Kassirer Asset Management Corp acquired a new stake in PharMerica during the 3rd quarter worth approximately $3,907,000. BNP Paribas Arbitrage SA lifted its position in shares of PharMerica by 45.7% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,815 shares of the company’s stock worth $522,000 after purchasing an additional 5,590 shares during the period. Swiss National Bank lifted its position in shares of PharMerica by 4.4% in the 3rd quarter. Swiss National Bank now owns 52,000 shares of the company’s stock worth $1,524,000 after purchasing an additional 2,200 shares during the period. Boston Partners lifted its position in shares of PharMerica by 4.4% in the 3rd quarter. Boston Partners now owns 1,436,519 shares of the company’s stock worth $42,090,000 after purchasing an additional 60,232 shares during the period. Finally, Gabelli Funds LLC acquired a new position in shares of PharMerica during the 3rd quarter valued at $5,645,000. Institutional investors and hedge funds own 89.97% of the company’s stock.

In other PharMerica news, CEO Gregory S. Weishar sold 521,089 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $29.25, for a total transaction of $15,241,853.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.04% of the stock is owned by corporate insiders.

A number of research firms recently issued reports on PMC. Zacks Investment Research downgraded shares of PharMerica from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. ValuEngine lowered shares of PharMerica from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. PharMerica currently has a consensus rating of “Hold” and a consensus price target of $30.50.

Shares of PharMerica Co. (NYSE:PMC) opened at $29.25 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.58 and a debt-to-equity ratio of 0.79. The stock has a market cap of $910.27, a price-to-earnings ratio of 47.95, a PEG ratio of 1.27 and a beta of 0.82. PharMerica Co. has a one year low of $22.00 and a one year high of $29.50.

PharMerica (NYSE:PMC) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.46 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.03). The company had revenue of $595.10 million during the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a return on equity of 2.30% and a net margin of 0.54%. research analysts expect that PharMerica Co. will post 1.92 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/01/12/new-york-state-common-retirement-fund-sells-17854-shares-of-pharmerica-co-pmc.html.

PharMerica Company Profile

Institutional Ownership by Quarter for PharMerica (NYSE:PMC)

Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply